1. Home
  2. BOLD vs PIII Comparison

BOLD vs PIII Comparison

Compare BOLD & PIII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BOLD
  • PIII
  • Stock Information
  • Founded
  • BOLD 2018
  • PIII 2015
  • Country
  • BOLD United States
  • PIII United States
  • Employees
  • BOLD N/A
  • PIII N/A
  • Industry
  • BOLD
  • PIII Medical/Nursing Services
  • Sector
  • BOLD
  • PIII Health Care
  • Exchange
  • BOLD Nasdaq
  • PIII Nasdaq
  • Market Cap
  • BOLD 24.4M
  • PIII 28.6M
  • IPO Year
  • BOLD 2024
  • PIII N/A
  • Fundamental
  • Price
  • BOLD $1.15
  • PIII $8.60
  • Analyst Decision
  • BOLD Buy
  • PIII Strong Buy
  • Analyst Count
  • BOLD 4
  • PIII 3
  • Target Price
  • BOLD $4.00
  • PIII $17.50
  • AVG Volume (30 Days)
  • BOLD 79.9K
  • PIII 7.3K
  • Earning Date
  • BOLD 11-06-2025
  • PIII 11-11-2025
  • Dividend Yield
  • BOLD N/A
  • PIII N/A
  • EPS Growth
  • BOLD N/A
  • PIII N/A
  • EPS
  • BOLD N/A
  • PIII N/A
  • Revenue
  • BOLD N/A
  • PIII $1,461,823,000.00
  • Revenue This Year
  • BOLD N/A
  • PIII N/A
  • Revenue Next Year
  • BOLD N/A
  • PIII $9.46
  • P/E Ratio
  • BOLD N/A
  • PIII N/A
  • Revenue Growth
  • BOLD N/A
  • PIII 4.20
  • 52 Week Low
  • BOLD $1.00
  • PIII $5.80
  • 52 Week High
  • BOLD $4.72
  • PIII $29.00
  • Technical
  • Relative Strength Index (RSI)
  • BOLD 49.88
  • PIII 66.37
  • Support Level
  • BOLD $1.13
  • PIII $8.46
  • Resistance Level
  • BOLD $1.16
  • PIII $8.90
  • Average True Range (ATR)
  • BOLD 0.04
  • PIII 0.32
  • MACD
  • BOLD 0.00
  • PIII 0.03
  • Stochastic Oscillator
  • BOLD 62.50
  • PIII 80.59

About BOLD Boundless Bio Inc. Common Stock

Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

About PIII P3 Health Partners Inc.

P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.

Share on Social Networks: